Wilson's Decuprate heading for Phase III

Wilson Therapeutics AB (SSE:WTX) said Decuprate bis-choline tetrathiomolybdate (WTX101) met the primary endpoint in a Phase II study to treat Wilson's disease, in which excess copper accumulates in the body. Next year, the company expects to begin a Phase III study of the second-generation analog of ammonium tetrathiomolybdate.

Wilson said that after 24 weeks of treatment, 79% of patients in the study's intent-to-treat population achieved or maintained normal levels of free copper, or had a 25% drop in free blood copper from baseline, to meet the primary endpoint (p<0.001). It also reported a 77% mean reduction in serum free copper at week 24 compared to baseline (p<0.0001), and significant improvement in neurological status (p<0.001) and disability (p<0.001). ...